153. The method of claim 152 wherein the protein synthesis inhibitor is cycloheximide.

154. The method of claim 142 wherein said activatedegg cytoplasm is treated with a chemical that inhibits at least one event or process promoted by activated-egg cytoplasm.

155. The method of claim 154 wherein said chemical is a phosphodiesterase inhibitor.

156. The method of claim 142 wherein said donor-cell nucleus is the nucleus of a non-dividing cell.

REMARKS

Presented herewith are claims 87-156. Claims 87 and 142 are independent claims.

Claims 87-141 and 144-146 are limited to methods that exclude sperm cells, i.e., cloning.

Cloning claims have not previously been considered for patentability by the Office. Cloning claims were previously presented by Applicant in priority application Serial No. 08/455,891, but were subject to a restriction requirement in that case. Claims 142-143 and 151-156 are generic to somatic and sperm cells, and claims 147-150 are specific to sperm cells. None of this claims, however, is of the same scope as the claims of U.S. Patent 5,773,217, which claims are specific to activation

of sperm cells using CSF extract.

CONCLUSION

Applicants maintain that claims 87-156 patentably define the invention and request that the Examiner permit the pending claims to pass to allowance.

If the Examiner would like to discuss any of the issues raised in this Preliminary Amendment, the Applicant's undersigned representative can be reached at the telephone number listed below.

Enclosed is a check for the filing fee. Please charge any additional fees or make any credits to Deposit Account No. 06-1150.

Date: 1/6/99

Respectfully submitted,

William J. Horse Reg. No. 26,739

Fish & Richardson P.C. 45 Rockefeller Plaza Suite 2800 New York, NY 10111

Telephone: 212/765-5070 Facsimile: 212/258-2291

42541.N11